TScan Therapeutics, Inc. TCRX
Regular-session close
After hours · Nov 19, 6:41 PM ET
- YTD
- -85.73%
- 1 year
- -86.15%
- Market cap
- 9.67M
- Revenue (ttm)
- 9.36M
- EPS (ttm)
- -0.89
- Shares out
- 49.09M
- Forward P/E
- -2.33
- YTD return
- -85.73%
- 1-year return
- -86.15%
- 50-day average
- 4.58
- 200-day average
- 6.31
- Volume
- 507.20K
- Avg volume
- 759.48K
- Open
- 0.1526
- Previous close
- 0.1484
- Day's range
- 0.1401 – 0.157
- 52-week range
- 0.14 – 1.47
- Beta
- 0.78
- Analysts
- Strong Buy
- Price target
- 12.14 (+8409.4%)
Key statistics
- Enterprise value
- -22.25M
- Price / sales
- 17.16
- Price / book
- 0.70
- Revenue growth
- -73.00%
- Free cash flow
- -71.11M
- Total cash
- 271.12M
- Total debt
- 90.36M
- Return on equity
- -55.92%
- Short % of float
- 6.00%
Fundamental scorecard
7 of 25 checks passed on TCRX’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.28 | -0.25 | +0.03 | +10.71% |
| Aug 12, 2024 | Jun 1, 2024 | -0.30 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.30 | -0.28 | +0.02 | +6.67% |
| May 13, 2024 | Mar 1, 2024 | -0.25 | -0.32 | -0.07 | -28.00% |
| May 13, 2024 | Mar 1, 2024 | -0.25 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 11, 2024 | Needham | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | Needham | reit | Buy | Buy |
| Nov 6, 2024 | Needham | reit | Buy | Buy |
| Aug 13, 2024 | Wedbush | reit | Outperform | Outperform |
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tscan.com
News
TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX)
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on TCRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBERICH TIMOTHY JOSEPH | Director | Purchase | Dec 18, 2023 | 100,286 |
| KLENCKE BARBARA M.D. | Director | Purchase | Sep 22, 2024 | 70,000 |
| LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 12, 2024 | 0 |
| SILVER BRIAN M. | Chief Financial Officer | Purchase | Dec 27, 2022 | 32,885 |
| ZDRAVESKI ZORAN | Officer | Sale | Aug 22, 2024 | 4,716 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 10.64% | 5,224,600 | 15.73M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 10.18% | 5,000,000 | 15.05M | Sep 29, 2024 |
| Blackrock Inc. | 9.44% | 4,632,876 | 13.94M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 8.96% | 4,400,000 | 13.24M | Sep 29, 2024 |
| BVF Inc. | 6.09% | 2,989,474 | 9.00M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 5.67% | 2,784,792 | 8.38M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.79% | 1,370,394 | 4.12M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 2.13% | 1,046,916 | 3.15M | Sep 29, 2024 |
| BlackRock Health Sciences Term Trust | 2.13% | 1,045,767 | 3.15M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.97% | 967,477 | 2.91M | Oct 30, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.39% | 681,015 | 2.05M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 645,510 | 1.94M | Sep 29, 2024 |
